Atlas Trials

Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810

Clinical trial NCT05526066 · TERMINATED

Trial details

NCT number
NCT05526066
Sponsor
Arcturus Therapeutics, Inc.
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Ornithine Transcarbamylase DeficiencyOTC DeficiencyOTCD
Start date
2022-10-17
Primary completion
2024-10-31
Enrollment
8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.